Summary. Vanadate and insulin were administered to diabetic (streptozotocin) rats to compare their effects on the activity and mRNA content of 6-phosphofructo-2-kinase and L-type pyruvate kinase in the liver. The activity of 6-phosphofructo-2-kinase in livers of diabetic rats was about 40 % of that found in normal rats. A similar decrease was found for 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase content, measured by immunoprecipitation, and for mRNA, measured by hybridization of Northern blots. Administration of vanadate to the diabetic rats led to a progressive recovery of 6-phosphofructo-2-kinase activity, and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase content and mRNA. This recovery, which was complete after 15 days of oral treatment, was also obtained after 60 h of insulin administration. L-type pyruvate kinase activity and mRNA were also decreased by about 70 % in livers of diabetic rats. Both parameters normalized after 15 days of vanadate treatment, whereas insulin administration (60 h) raised L-pyruvate kinase mRNA three-fold above control values. Oral treatment for 15 days with vanadate can thus mimic the effect of insulin on both pyruvate kinase and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in livers of diabetic rats.
Vanadium compounds mimic most of the actions of insulin in intact cells [1] [2] [3] [4] [5] [6] [7] and in the whole animal [8] [9] [10] [11] [12] . One of the most interesting "in vivo" effects of vanadate is its ability to normalize the high blood glucose of rats with streptozotocin-induced diabetes [8] [9] [10] . In these animals, vanadate does not increase serum insulin levels [8] , suggesting that insulin target tissues themselves are the site of vanadate action. Furthermore, the oral administration of vanadate leads to normoglycaemia by stimulating glucose uptake in liver and muscle [9] . In skeletal muscle [11] and liver [12] , vanadate reverses the defect in glycogen synthesis of diabetic animals, and does not modify the insulin binding characteristics [13, 14] .
In a previous paper [10] , we demonstrated that additional effects of vanadate on hepatic carbohydrate metabolism could also be involved in the reduction of plasma glucose concentration after its oral administration to diabetic rats. Vanadate normalized glucokinase activity, which was almost absent in the liver of diabetic animals. The increase in glucokinase activity was due to an increase in its mRNA [15] and was correlated with the increase in glucose uptake [9] . Furthermore, vanadate activated hepatic glucose consumption through an increase in fructose 2,6-bisphosphate (Fru-2,6-P2) and 6-phosphofructo-2-kinase (PFK-2) activity [10, 16] . Fru-2,6-P2 is indeed a potent stimulator of glycolysis and inhibitor of gluconeogenesis in liver [17] [18] [19] . The concentration of Fru-2,6-P2 depends on the balance between the activities of PFK-2 and fructose 2,6-bisphosphatase (FBPase-2), which respectively catalyses its synthesis and breakdown [17] [18] [19] . It has been reported that the mRNA level for liver PFK-2/ FBPase-2 does not decrease in starvation or diabetes despite a decrease in PFK-2 enzyme content [20, 21] . However, it has also been shown that feeding after starvation or insulin administration to diabetic rats causes co-ordinate increases in the liver bifunctional enzyme and its mRNA [21] . The aim of the present work was to study the effect of oral vanadate administration to diabetic rats on liver PFK-2 activity, and on PFK-2/FBPase-2 content and mRNA levels. We also determined the activity and the mRNA level of hepatic L-type pyruvate kinase (L-PK).
Materials and methods

Chemicals
All reagents were of the best grade commercially available.
[~-32p]dCTP (3000 Ci/mmol), multiprime DNA labelling system, and nylon membranes were from Amersham International plc (Amersham, Bucks, UK). Nitrocellulose membranes were from Schleicher & Schuell (Dassel, FRG). Protein A Sepharose CL-4B was from Pharmacia (Uppsala, Sweden). RNA ladder was from Bethesda Research Laboratories (Gaithersburg, Md, USA). Sodium orthovanadate (Na3VO4) and streptozotocin were from Sigma (St. Louis, Mo., USA).
Animals
Male Sprague-Dawley rats weighing 200-250 g were used. Diabetes was induced by a single intravenous injection of streptozotocin (60mg/kg) dissolved in 0.5ml of 50mmol/1 sodium citrate, 0.15 mol/1 NaC1, pH 4.5. Control rats received the buffer only. One week later, blood samples were collected from the tail vein for glucose determination. Animals whose glycaemia exceeded 19 mmol/1 were considered to be diabetic. Streptozotocin-injected animals treated with vanadate were given water containing NaC1 (0.5 g/100 ml) and sodium orthovanadate (70 mg/100 ml), prepared fleshly everyday. The control groups of animals were given a 0.5 g/100 ml NaC1 solution. Diabetes was assessed periodically by testing for glucosuria (Urotron; Boehringer, Mannheim, FRG). Diabetic rats treated with insulin (Actrapid; Novo Industri, Copenhagen, Denmark) received 30 IU/kg subcutaneously at 8-h intervals over 60 h. Animals were killed by decapitation 1-2 h after the last insulin dose. Blood samples were collected at the time of death, and the livers were freeze-clamped in liquid nitrogen and stored at -70 ~ prior to extraction.
Assays of enzymes and metabolites
PFK-2 activity was measured as described [22] , using the assay at pH 8.5 which yields the "total" activity and which is not affected by the phosphorylation state of the enzyme [22] . Total L-PK activity was measured at 5 mmol/1 phosphoenolpyruvate as described [23] . One unit of enzyme activity corresponds to i ~tmol of substrate used per min, under the conditions of the assay. Blood glucose was assayed as described [24] . Protein was determined according to Bradford [25] , with bovine serum albumin as a standard.
Immunotitration of liver PFK-2/FB Pase-2
To obtain liver cytosol, samples were homogenized (Potter-E1-vejhem homogenizer) in 3 volumes of an ice-cold solution containing 50 mmol/1 KC1, 2 mmol/1 EDTA, 5 mmol/1 MgC12, 15 mmol/1 fl-mercaptoethanol, 0.1 mmol/1 phenylmethylsulphonyl fluoride, leupeptin (8 gg/ml), aprotinin (16 gg/ml), 20 mmol/1 Hepes and i mmol/1 phosphate, pH 7.0, and centrifuged at 10 000 x g for 20 rain followed by 105 000 x g for 60 rain at 4 ~ PFK-2 immunotitration was carried out as described [20] . Briefly, a fixed volume of cytosol (1.5 mg cytosol protein/ml) and up to 10 gl of the (BCL-2) anti-PFK-2 antiserum were incubated in 0.2 ml containing 100 mmol/1 KC1, 15 mmol/1 fl-mercaptoethanol, 20 mmol/1Tris, pH 8.0, 0.1% bovine serum albumin, 75 gl of protein A-Sepharose suspension (1:1). After 30 min of agitation at room temperature, the immune complexes were precipitated (8000 x g, 4 min, 4~ and the residual PFK-2 activity was measured in the supernatant. The liver PFK-2 content is expressed as the volume of BCL-2 antiserum required to precipitate 50 % of PFK-2 activity in the presence of protein A-Sepharose. It was calculated from the logit plots of immunotitration curves [20] .
Determination of mRNA by hybridization
Total RNA was extracted from livers by a modified [26] guanidium thiocyanate method [27] . The concentration of total RNA was measured by spectrophotometry (A2~A280) and its integrity was M. Miralpeix et al.: Vanadate increases PFK-2 content and mRNA systematically verified by electrophoresis in agarose submarine minigels stained with ethidium bromide. Dot blot and Northern blot analyses were performed as described [20, 28] . Filters were hybridized with a 1.4 kilobase (kb) rat liver PFK-2/FBPase-2 cDNA probe (22cl), which corresponds to the mRNA for liver PFK-2/FBPase-2 devoid of the 5' end coding for amino acids 1 to 90 [28] . Chicken fl-actin and rat liver L-PK cDNA probes were used as controls [20, 28] . cDNA probes were labelled with [~-32P]dCTP by the multiprime system. The intensity of hybridization was measured by scanning the autoradiograms using a Chromoscan 3 Joyce Loebl densitometer.
Statistical analysis
Differences between experimental groups were tested by an analysis of variance (ANOVA) and the appropriate linear contrasts (analysed using Scheffe's critical value, to adjust for multiple comparisons) for the differences vs control or diabetic group. In all tests, a significance level ofp < 0.05 was used.
Results
To assess the effects of streptozotocin and of oral administration of vanadate, we determined the blood glucose concentration in the different experimental groups of rats. Glycaemia was lowered after vanadate treatment of the diabetic animals, and normalized after 15 days of treatment (Table 1) , confirming earlier work [8] [9] [10] 12] . We also determined L-PK activity, which is known to decrease in diabetic rats and be restored to normal upon insulin treatment [29] , and found this to be the case (Table 1) . We then determined liver PFK-2 activity and PFK-2/FBPase-2 content. Consistent with earlier reports [20, 30] , we found that PFK-2 activity in diabetic rats fell to about 40 % of the control values, and that vanadate treatment [10] , or insulin administration [30] increased the low hepatic PFK-2 activity of diabetic rats (Table 1) , but to a different extent and with a different time-course. Insulin treatment for 60 h raised PFK-2 activity to normal values, whereas the activity was normalized only after 5-7 days of vanadate administration. We also determined by immunotitration ( Fig. 1) whether this effect of insulin and vanadate resulted from an increased fiver PFK-2/FBPase-2 content, which was found to be the case ( Fig. 1 and Table 1 ). As to the L-PK activity of diabetic rats it was also normalized by vanadate treatment (Table 1) .
To determine whether the increase in liver PFK-2/FBPase-2 content observed with vanadate treatment was due to an increase in PFK-2/FBPase-2 mRNA levels, dot blot (not shown) and Northern blot (Fig. 2, 3) hybridizations were performed with total hepatic RNA obtained from the rats of the different experimental groups. fl-Actin mRNA of each sample was also measured because it is a standard reference for the amount of mRNA present [20, 31] . However, we found (not shown) that insulin treatment increased significantly the levels of fl-actin mRNA, in keeping with an earlier report [32] . This made it impossible to use fl-actin mRNA as an internal control. We therefore hybridized liver RNA from all the experimental groups with a cDNA probe specific for L-PK mRNA. Indeed, L-PK mRNA concentration decreases in diabetes, and increases following insulin administration [32, 33] . Moreover, vanadate can mimic insulin by increasing L-PK mRNA in cultured hepatocytes [15] . As expected, L-PK mRNA level was reduced to 15 % of the control value in the liver of diabetic rats. Both insulin and vanadate increased the content of mRNA for L-PK in diabetic rat liver, but to a different extent (Fig. 4) . Insulin administration for 60 h raised L-PK mRNA three-fold above control values, while vanadate treatment during 2weeks normalized L-PK mRNA content. Based on these results, we inferred that our methodology was appropriate to assess the effect of vanadate on PFK-2/FBPase-2 mRNA. Northern blot analysis (Fig.2) showed that PFK-2/FBPase-2 mRNA has the length (2.1 kb) expected for the liver isozyme [28] . Data in Figures 2 and 3 show that the hepatic PFK-2/FBPase-2 mRNA was significantly decreased by diabetes compared with control levels. This is at odds with previous results in which no change was seen volume of serum adde0 (~l) Fig.1 . Immunotitration of liver PFK-2. The enzyme activity was measured at pH 8.5 after immunoprecipitation. All incubations contained 1.5 mg of cytosolic protein/ml, protein A-Sepharose, and different volumes of BCL-2 antiserum. Total 6-phosphofructo 2-kinase (PFK-2) was 66 gU/mg protein in the control rat ( 9 15 gU/mg protein in the diabetic rat ( 9 55 gU/mg protein in the diabetic rat treated with vanadate for 15 days (A) and 59 gU/mg protein in "the diabetic rat treated with insulin for 60 h ([]). Each curve corresponds to one representative animal (i. e., with the values closest to its group mean) from each experimental group [20, 21] . This discrepancy could be due to the smaller number of animals and the resulting large variability of the values [21] , or to the fact that diabetes was induced by alloxan instead of streptozotocin and therefore perhaps less severe [20] . Insulin administration for 60 h resulted in an increase of the PFK-2/FBPase-2 mRNA content above control values (Fig. 3 ). This effect was less than that observed [21] after 48 h of insulin treatment as if the amount of PFK-2/FBPase-2 mRNA would begin to decline toward the control value, as it did after 96 h of feeding [21] . Compared to insulin administration, vanadate treatment of diabetic animals produced a slow and progressive increase of PFK-2/FBPase-2 mRNA content, which reached a normal value after 15 days of treatment (Figs. 2,   3 ).
Discussion
The results reported in this paper show that oral vanadate treatment of streptozotocin-diabetic rats leads to a recovery of glycaemia and of hepatic Fru-2,6-P2 concentration, as well as PFK-2 and L-PK activities. PFK-2 immunotitration indicated that changes in PFK-2 activity during diabetes and upon insulin or vanadate administration reflect changes in the amount of enzyme. This interpretation is in line with the observation that vanadate and insulin induce the synthesis of PFK-2/FBPase-2 enzyme in cultured rat hepatocytes [16] . L-PK activity of diabetic rats was also normalized by vanadate treatment. The oral treatment of diabetic animals with vanadate for 15 days restores PFK-2/FBPase-2 and L-PK mRNAs levels. The time-course and the effectiveness of vanadate treatment were different than those of insulin. Vanadate produced a slow and progressive increase of PFK-2/FBPase-2 mRNA but did not reach the values obtained after insulin administration. These differences could probably be due to the different administration route and mechanism of action of vanadate.
There is a lag period of at least 6 h between injection of insulin and the increase in PFK-2/FBPase-2 [20] and L-PK [33] mRNAs. Noguchi et al. [33] have suggested that insulin may increase transcription of the L-PK gene by stimulating the synthesis of some unknown protein. Recently, Miralpeix et al. [15] have shown that vanadate mimics insulin action on L-PK and glucokinase transcription and, similar to Fig.3 . Northern blot analysis of liver 6-phosphofructo 2-kinase (PFK-2) fructose 2,6-bisphosphatase mRNA. Total liver RNA from control rats (C, n = 4), diabetic rats (D, n = 8), diabetic rats treated with vanadate (V) for 3 days (V3, n = 5), 5 days (V5, n = 5), 7 days (V7, n = 5) or 15 days (V15, n = 5) and diabetic rats treated with insulin (I, n = 4) was electrophoresed and transferred to a nylon membrane. The relative amounts of mRNA were quantitated using a densitometer. The results are expressed in arbitrary units as means + SEM for the specified number of rats indicated. * p < 0.05 vs control rats insulin [34] , vanadate cannot increase the L-type PK m R N A content in the absence of glucose. This indicates that neither vanadate nor insulin has a direct role on transcription of the L-type P K gene by itself, since glucose is required for its mechanism of action. The intracellular signalling mechanism used by insulin to control PFK-2/FBPase-2 m R N A is not known. Cifuentes et al. [35] The filters were hybridized with the L-PK cDNA probe. Autoradiograms of the filters were scanned with a densitometer. A representative experiment is shown at the right. For each RNA sample, the slope of the linear relationship between gg RNA spotted and integration units (e. g. integration units/gg RNA) was calculated (for all samples, r 2 < 0.98). The chart on the left shows the mean and SEM of the slopes for each group. * p < 0.05 vs control rats
Insulin stimulates the expression of several genes including those encoding glyceraldehyde-3-phosphate dehydrogenase, C-Fos, gene 33 product and a-amylase [36] . In contrast, insulin inhibits the expression the phosphoenolpyruvate carboxykinase, adipsin and growth horm o n e genes [36] . Similarly to insulin, vanadate can stimulate the expression of C-Fos [37] , a-amylase [38] , glucokinase and L-PK in hepatocyte cultures [15] , and PFK-2 and L-PK in diabetic rat liver as shown here. Vanadate can also inhibit the expression of phosphoenolpyruvate carboxykinase [39] . The similarity of actions of insulin and vanadate suggest that both agents could act via a c o m m o n pathway. The exact site of action of vanadate remains uncertain. Considerable evidence suggests that insulin-receptor kinase activity plays an essential role in at least some of the intracellular actions of insulin [40] . Accordingly, it has been proposed that vanadate m a y exert insulin-mimetic effects by maintaining insulin receptor and other endogenous proteins in an appropriate state of phosphorylation as a result of activation of the insulin receptor kinase [3, 41] and/or an inhibition of phosphotyrosine phosphatases [42] . However, the lack of effect of vanadate on the level of tyrosine phosphorylation of t-insulin receptor found by several authors [14, [43] [44] [45] [46] , and the fact that vanadate stimulates glucose transport in adipocytes that had been treated with trypsin or insulin and Tris to decrease insulin-receptor concentration [4] suggest that its primary action m a y be at a step distal to the insulin receptor.
In conclusion, our results show that vanadate can also mimic some insulin actions on gene expression, explaining the recovery of the diabetic animals after oral vanadate treatment [10] .
